The landscape of metabolic medicine is undergoing a seismic shift as biotechnology firms move beyond the current generation of appetite-suppressing injectables toward more targeted, tissue-specific interventions. Moonwalk Biosciences, a pioneer in the development of adipose-targeted RNA interference (RNAi) therapeutics, solidified its position in this evolving market on September 8 with the announcement of a $70 million Series B financing round. This oversubscribed funding cycle underscores a growing investor appetite for "non-incretin" pathways—treatments that address obesity and cardiometabolic diseases by modulating the biology of fat tissue directly, rather than focusing primarily on the brain’s hunger signals.
The financing round was co-led by Alpha Wave and YK Bioventures, attracting a high-profile syndicate of investors including Eli Lilly and Company, Gaorong Ventures, and existing backers ARCH Venture Partners, Khosla Ventures, and Future Ventures. The capital infusion is earmarked for the clinical advancement of Moonwalk’s lead obesity candidate, MW101, which is slated for first-in-human trials in late 2027. Beyond its lead asset, the company intends to utilize the funds to broaden its pipeline of tissue-targeted small interfering RNA (siRNA) medicines and refine its proprietary discovery platform.
The Evolution of Obesity Therapeutics: Moving Beyond Incretins
For the past several years, the obesity treatment market has been dominated by incretin mimetics—GLP-1 and GIP receptor agonists that primarily function by slowing gastric emptying and signaling satiety to the brain. While these drugs have demonstrated unprecedented weight loss results, they are often associated with gastrointestinal side effects and a significant loss of lean muscle mass. Moonwalk Biosciences is pursuing a fundamentally different biological route.
Moonwalk’s approach centers on the use of siRNA to selectively silence genes within adipose tissue (fat cells). By targeting the fat tissue directly, the company aims to modulate pathways involved in energy homeostasis, adipogenesis (the formation of fat cells), lipolysis (the breakdown of fats), and thermogenesis (the production of heat). This method allows for the precise regulation of metabolic health without affecting the central nervous system or appetite, potentially offering a more tolerable and durable solution for patients who do not respond well to or cannot tolerate current therapies.
The core of Moonwalk’s innovation lies in its ability to overcome the historical challenge of delivering RNAi therapies to specific tissues. While the liver has traditionally been the primary target for RNAi drugs due to its natural uptake mechanisms, Moonwalk utilizes proprietary tissue-targeting chemistry licensed from Suzhou Siran Biotechnology Co., Ltd. This chemistry allows their siRNA molecules to bypass the liver and concentrate in adipose tissue, minimizing off-target effects and enabling a highly specific therapeutic profile.
Strategic Leadership and the Path to Clinical Trials
The appointment of Dr. Stephen Djedjos as Senior Vice President of Clinical Development marks a strategic milestone for the company as it transitions from a discovery-stage entity to a clinical-stage organization. Dr. Djedjos brings a wealth of experience from his previous roles at Kailera Therapeutics, Mineralys Therapeutics, and Amgen. Notably, his work at Amgen contributed to the development and approval of Repatha, a blockbuster cholesterol medication. As a pediatric endocrinologist trained at Johns Hopkins, Djedjos’s background bridges the gap between complex molecular biology and the practicalities of patient care in metabolic disease.
Under this leadership, Moonwalk has already generated compelling preclinical data. In multiple studies, the company’s candidates have demonstrated the ability to reduce body weight and fat mass while preserving lean muscle—a "holy grail" in obesity research. Furthermore, non-human primate studies have indicated that a single dose can result in durable adipose target engagement. This suggests a future where patients may only require quarterly or even biannual dosing, a significant improvement over the weekly injections required by current GLP-1 therapies.
The timeline for MW101 is now clearly defined. With the Series B funding secured, Moonwalk will complete ongoing Investigational New Drug (IND)-enabling studies through 2026, setting the stage for the 2027 clinical debut. This long-term horizon reflects the rigorous safety and efficacy standards required for a new class of genetic medicine.
Medically Modern: Streamlining the Infrastructure of Diabetes Care
While Moonwalk Biosciences focuses on the future of metabolic pharmacology, Medically Modern is addressing the immediate operational challenges of modern endocrinology. On the same day as Moonwalk’s announcement, Medically Modern, a national durable medical equipment (DME) supplier, unveiled a strategic partnership with a major independent endocrinology practice in Northern Virginia. This partnership highlights a growing trend in healthcare: the outsourcing of administrative "pain points" to specialized technology-driven partners.
The Northern Virginia practice, which manages a patient population of over 10,000 individuals with diabetes, will now utilize Medically Modern’s platform to handle the complex logistics of Continuous Glucose Monitors (CGM) and insulin pump referrals. The primary goal is to alleviate the "paperwork drowning" that many specialized clinics face when prescribing advanced diabetes technology.
Solving the Administrative Crisis in Endocrinology
The administrative burden in US healthcare is a well-documented driver of physician burnout. For endocrinologists, the process of securing insurance approval for CGMs and insulin pumps is particularly arduous. It involves navigating varying pharmacy versus DME benefit structures, verifying medical necessity, and ensuring that patients meet specific "six-month visit" requirements mandated by payers for continued coverage.
Medically Modern’s model integrates directly into the practice’s workflow. The platform provides real-time visibility into the status of every referral—from the initial documentation to insurance verification and the final shipment of supplies. Crucially, the technology tracks the date of a patient’s last clinical visit. When a patient approaches the six-month mark without a scheduled appointment, the system alerts the practice, allowing them to proactively schedule the patient and prevent a disruption in their life-saving supplies.
Corey Deutsch, founder and CEO of Medically Modern, emphasized that this strategy was born out of direct feedback from providers. "Our team knows the coverage process inside and out," Deutsch stated. "By combining that expertise with tailored technology, we give providers time back to focus on clinical care rather than insurance processing."
Data-Driven Compliance and Market Expansion
In an era of increased regulatory scrutiny, Medically Modern has built its partnership model on a foundation of strict compliance. The company operates under executed business associate agreements (BAAs) and maintains policies that adhere to HIPAA, the federal Anti-Kickback Statute, and the Stark Law. This focus on compliance is essential for large-scale practices that must balance efficient operations with legal integrity.
The partnership in Northern Virginia serves as a scalable blueprint for Medically Modern’s national expansion. By working with leading manufacturers of diabetes technology and serving patients across Medicare, Medicare Advantage, and major commercial payers, the company is positioning itself as a vital intermediary in the diabetes supply chain. As technology like CGMs becomes the standard of care for both Type 1 and Type 2 diabetes, the demand for streamlined fulfillment services is expected to rise exponentially.
Broader Implications for the Cardiometabolic Sector
The simultaneous developments at Moonwalk Biosciences and Medically Modern represent two sides of the same coin: the modernization of metabolic health. On one side, Moonwalk is pushing the boundaries of what is biologically possible, utilizing AI-enabled discovery and epigenomics to create more precise medicines. On the other, Medically Modern is ensuring that the technological tools we already have are delivered to patients with maximum efficiency and minimum administrative friction.
The involvement of Eli Lilly in Moonwalk’s Series B is particularly telling. As one of the two dominant players in the obesity market (alongside Novo Nordisk), Lilly’s investment suggests a strategic interest in diversifying its portfolio beyond incretins. It signals an industry-wide recognition that the next phase of the obesity war will be fought on the grounds of "quality of weight loss"—specifically, the preservation of muscle mass and the improvement of metabolic health markers beyond simple poundage reduction.
Furthermore, the rise of "epigenetic" and "multi-omic" approaches in biotech, as seen with Moonwalk, indicates that the future of medicine is becoming increasingly personalized. By understanding the specific genetic and epigenetic drivers of fat storage and energy use in an individual, researchers can develop therapies that work with the body’s natural systems rather than overriding them.
Conclusion: A Synergistic Future for Patient Outcomes
The advancement of Moonwalk’s RNAi platform and the expansion of Medically Modern’s operational partnership model reflect a maturing ecosystem for cardiometabolic care. As obesity and diabetes continue to pose significant global health challenges, the combination of breakthrough science and operational excellence will be required to move the needle on patient outcomes.
For the millions of people living with these conditions, the news of a $70 million investment into non-appetite-based therapies offers hope for treatments that are easier to maintain and better for long-term physical health. Meanwhile, for the clinicians on the front lines, the growth of support systems like Medically Modern promises a future where the focus remains on the patient, not the paperwork. As Moonwalk moves toward its 2027 clinical milestones and Medically Modern expands its footprint, the integration of high-science and high-efficiency remains the most viable path forward for the field of endocrinology.
